CoFI System for MVO
Microvascular Obstruction in ST-elevation myocardial infarction (STEMI) patients
Pivotal TrialActive
Key Facts
Indication
Microvascular Obstruction in ST-elevation myocardial infarction (STEMI) patients
Phase
Pivotal Trial
Status
Active
Company
About CorFlow Therapeutics
CorFlow Therapeutics is developing the CoFI System, a novel interventional device aimed at addressing the critical unmet need of microvascular obstruction (MVO) following a heart attack. The system is designed to seamlessly integrate into the existing PCI workflow to both diagnose MVO in real-time and potentially deliver targeted therapeutics. With clinical data pending from its MOCA trials, CorFlow is positioning itself to potentially improve long-term cardiac outcomes by enabling early detection and intervention for a complication that currently lacks a routine intra-procedural solution.
View full company profile